CompletedPHASE1, PHASE2NCT00233519

Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)

Studying Chronic bilirubin encephalopathy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Rochester
Principal Investigator
Richard T. Moxley, III, M.D.
University of Rochester
Intervention
SomatoKine/IPLEX(drug)
Enrollment
17 enrolled
Eligibility
21-60 years · All sexes
Timeline
20052008

Study locations (1)

Collaborators

National Institute of Neurological Disorders and Stroke (NINDS) · Imsmed Incorporated

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00233519 on ClinicalTrials.gov

Other trials for Chronic bilirubin encephalopathy

Additional recruiting or active studies for the same condition.

See all trials for Chronic bilirubin encephalopathy

← Back to all trials